References
- Bemheimer H, Birkmayer W, Homykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-55 https://doi.org/10.1016/0022-510X(73)90175-5
- Hornykiewicz O, Kish SJ. Biochemical physiology of Parkinson's disease. Arch Neuro 1987;45:19-23
- Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopaminergic loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-80 https://doi.org/10.1056/NEJM198804073181402
- Rinne JO, Laihinen A, Nagren K, Bergman J, Solin O, Haaparanta M, et al. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease. J Neurosci Res 1990;27:494-9 https://doi.org/10.1002/jnr.490270409
- Booij J, Tissingh G, Winogrodzka A, van Royen EA Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999;26:171-82 https://doi.org/10.1007/s002590050374
-
Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, et al. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [
$^{123}$ I]IPT and single-photon emission tomography. Eur J Nucl Med 1997;24:415-21 https://doi.org/10.1007/BF00881814 - Goto S, Hirano A, Matsumoto S. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration. Ann Neurol 1989;26:766-70 https://doi.org/10.1002/ana.410260613
-
Hirai M, Kitamura N, Hashimoto T, Nakai T, Mita T, Shirakawa O, et al. [
$^{3}$ H]GBR-12935 binding sites in human striatal membranes: binding characteristics and changes in parkinsonians and schizophrenics. Jpn J Pharmacol 1988;47:237-43 https://doi.org/10.1254/jjp.47.237 -
Janowsky A, Vocci F, Berger P, Angel I, Zelnik N, Kleinman JE, et al. [
$^{3}$ H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease. J Neurochem 1987;49:617-21 https://doi.org/10.1111/j.1471-4159.1987.tb02908.x -
Maloteaux JM, Vanisberg MA, Laterre C, Javoy-Agid F, Agid Y, Laduron PM [
$^{3}$ H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. Eur J Pharmacol 1988;156:331-40 https://doi.org/10.1016/0014-2999(88)90278-6 - Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983;275:321-8 https://doi.org/10.1016/0006-8993(83)90993-9
- Ciliax BJ, Heilman C, Demchyshyn LL, Pristupa ZB, Ince E, Hersch SM, et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 1995;15:1714-23
- Church WH, Justice JB Jr, Byrd LD. Extracellular dopamine in rat striatum following uptake inhibition by cocaine, nomifensine and benztropine. Eur J Pharmacol 1987;139:345-8 https://doi.org/10.1016/0014-2999(87)90592-9
- Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, Macgregor RR, et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 1989;4:371-7 https://doi.org/10.1002/syn.890040412
- Hurd YL, Ungerstedt U. Cocaine: an in vivo microdialysis evaluation of its acute action on dopamine transmission in rat striatum. Synapse 1989;3:48-54 https://doi.org/10.1002/syn.890030107
- Huang WS Lin SZ, Lin JC, Wey SP, Ting G, Liu RS. Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging. J Nucl Med 2001;42:1303-8
- Kim HJ, Lim JH, Yang SO, Ryu JS, Choi YY, Lee MJ et al. I-123 IPT SPECT Dopamine Reuptake Site Imaging: Differences in Normal Controls and Parkinson's Patients by Semiquantitative analysis. Korean J Nuc Med 1996;30:35-46
- Kim HJ, Im JH, Yang SO, Moon DH, Ryu JS, Bong JK, et al. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects. J Nucl Med 1997;38:1703-11
-
Im JH, Chung SJ, Kim JS, Lee MC. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: Analysis with [
$^{123}I$ ]IPT single photon emission computed tomography. J Neurol Sciences 2008;244:103-9 - Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. Eur J Nucl Med Mol Imaging. 2009;36;454-62 https://doi.org/10.1007/s00259-008-0989-5
- Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-81 https://doi.org/10.1136/jnnp.57.6.672
- Johnson KA, Davis KR, Buonanno FS, Brady TJ, Rosen TJ, Growdon JH. Comparison of magnetic resonance and Roentgen ray computed tomography in dementia. Arch Neurol 1987;44:1075-80 https://doi.org/10.1001/archneur.1987.00520220071020
- Kohira I. The use of magnetic resonance imaging (MRI) and single photon emission computing tomography (SPECT) for the differential diagnosis of Parkinson's disease and other neurodegenerative disorders presenting as parkinsonism. Nippon Binsho 1997;55:39-42
- Okada J, Peppard R, Calne DB. Comparison study of positron emission tomography, X-ray CT and MRI in parkinsonism with dementia. Nippon Igaku Hoshasen Gakkai Zasshi 1989;49:643-56
-
Liu RS, Lin KN, Wang SJ, Shan DE, Fuh JL, Yeh SH, et al. Cognition and
$^{99}m$ Tc-HMPAO SPECT in Parkinson's disease. Nucl Med Commun 1992;13:744-8 https://doi.org/10.1097/00006231-199213100-00007 - Kim HJ, Bong JK, Lee HK. Comparison Studies of SPECT Dopamine Transporter Imaging and Noninvasive Quantification using Tc-99m TRODAT-1 and I-123 IPT. Korean J Nuc Med 1998;32:10-19
- Bao SY Wu JC, Lo WF, Fang P, Liu ZL, Tang J. Imaging of dopamine transporters with technetirun-99m TRODAT-1 and single photon emission computed tomography. J Neuroimaging 2000;10:200-3 https://doi.org/10.1111/jon2000104200
- Madras BK, Jones AG, Mahmood A, Zimmerman RE, Garada B, Holman BL, et al. Technepine: a high-affmity 99m-technetirun probe to label the dopamine transporter in brain by SPECT imaging. Synapse 1996;22:239-46 https://doi.org/10.1002/(SICI)1098-2396(199603)22:3<239::AID-SYN6>3.0.CO;2-D
-
Mozley PD, Schneider JS, Acton PD, Plossl K, Stern MB, Siderowf A, et al. Binding of [
$^{99m}$ ]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 2000;41:584-9 - Mozley PD, Kim HJ, Gur RC, Tatsch K, Muenz LR, McElgin WT, et al. lodine-123-IPT SPECT imaging of CNS dopamine transporters: nonlinear effects of normal aging on striatal uptake values. J Nucl Med 1996;37:1965-70
- Britton TC. Essential tremor and its variants. Curr Opin Neurol 1995;8:314-9 https://doi.org/10.1097/00019052-199508000-00012
-
Brooks DJ, Ibanez V, Sawle GY, Playford ED, Quinn N, Mathias CJ, et al. Striatal D2 receptor status in patients with Parkinson's disease, strionigral degeneration and progressive supranuclear palsy, measured with
$^{11}$ C-raclopride and positron emission tomography. Ann Neurol 1992;31:184-92 https://doi.org/10.1002/ana.410310209 -
Lee MS, Kim YD, Im JH, Kim HJ, Rinne JO, Bhatia KP.
$^{123}$ I_IPT brain SPECT study in essential tremor and Parkinson's disease. Neurology 1999;52:1422-6 https://doi.org/10.1212/WNL.52.7.1422